ARAYARAYHealthcare · Medical Devices

ARAY Stock Forecast: Accuray, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.08
−2.12% on the day

The median 12-month analyst price target for Accuray, Inc. is $0.35. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 46 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$6.4M
Ticker Nerd rank
46/ 100
Median analyst target
$0.35
Analysts covering
1
Revenue$100.9M−20.9% y/y
Operating income$6.3M
Net income−$1.9M
Free cash flow$1.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−25.9%
1M
−62.9%
YTD
−93.7%
1Y
−94.5%
From 52W high
−95.3%
From 52W low
0.0%
$2
$44
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Accuray, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
46/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
74
Value
69
Accruals
60
Quality
51
Growth
45
Volatility
21
Revisions
20
Momentum
19

Issuance (74): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (19): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ARAY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARAY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26ARAYHigh $0.35Median $0.35Low $0.35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0
Buy
1
Hold
0
Sell
$0.35
Low
$0.35
Median
$0.35
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 May 2026JefferiesDowngradeHold$3.50 → $0.35
7 May 2026BTIGDowngradeNeutral—
5 Feb 2026BTIGMaintainsBuy—
6 Nov 2025BTIGMaintainsBuy—
14 Aug 2025BTIGMaintainsBuy—
13 Feb 2024Roth MKMInitiatesBuy—
4 Oct 2023B. Riley SecuritiesReiteratesBuy—
31 Aug 2022B. Riley SecuritiesInitiatesBuy—
24 June 2022BTIGMaintainsBuy—
23 June 2022B. Riley SecuritiesInitiatesBuy—
22 Dec 2021Loop CapitalInitiatesBuy—
21 Jan 2020BTIGUpgradeBuy—
21 Jan 2020BTIG ResearchUpgradeBuy—
1 Nov 2018CitigroupUpgradeNeutral—
17 Aug 2018CitigroupMaintainsSell—
19 Dec 2017JP MorganDowngradeUnderweight—
13 Dec 2017JP MorganDowngradeUnderweight—
30 Nov 2017Lake StreetInitiatesBuy—
23 Aug 2017JefferiesMaintainsBuy—
6 Feb 2017Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ARAY.

Market Radar

This page is one stock. Monday covers all of them.

ARAY appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ARAY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Accuray, Inc. returned −94.5% against +6.9% for the S&P 500, dividends included.

ARAY vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ARAYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARAY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.0×

Cheaper than 99% of US stocks

Price / book
0.1×

Cheaper than 95% of US stocks

EV / EBITDA
23.8×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
34.8%

Higher than 41% of US stocks

Operating margin
−0.6%

Higher than 34% of US stocks

Net margin
—
Returns & dividend
Return on equity
−30.2%

Higher than 28% of US stocks

Return on assets
−0.4%

Higher than 42% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Accuray, Inc. has a market value of $6.4M and an enterprise value of $100.1M.

  • Revenue in the twelve months to 30 June 2026: $401.9M. The latest quarter shrank 20.9% year on year.

  • Net income over the same four quarters: −$49.2M, a −12.2% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.40.

  • Free cash flow in the twelve months to 30 June 2026: −$19.3M, after $6.4M of capital spending.

  • Shares outstanding: 119.4M.

  • Accuray, Inc. employs 809 people — $497K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ARAY and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ARAYAccuray, Inc.$6.4M46
NMTCNeuroOne Medical Technologies Corp.$5.9M36
VNRXVolitionRX Ltd.$5.8M53
POASPhaos Technology Holdings (Cayman) Ltd.$5.1M2
BDMDBaird Medical Investment Holdings Ltd.$5.1M59
IRIXIRIDEX Corp.$7.6M47
BMRABiomerica, Inc.$5.0M11

Take a look at ARAY’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Accuray, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ARAY

What is the ARAY stock price forecast for 2026-2027?

The median 12-month analyst price target for Accuray, Inc. is $0.35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARAY stock a buy right now?

Of the 1 analyst covering Accuray, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Accuray, Inc. 46 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARAY?

As at 21 Nov 2026, Accuray, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (74 of 100).

Will ARAY stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $0.35, and Ticker Nerd's factor model ranks Accuray, Inc. 46 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARAY stock forecast for 2030?

No analyst covering Accuray, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.35 to $0.35 over the next 12 months.

How has ARAY stock performed over the past year?

Accuray, Inc. returned -94.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Accuray, Inc. do?

Accuray Incorporated is a medical device company that develops, manufactures, sells, and supports advanced radiation therapy systems for cancer treatment. The company’s portfolio centers on the CyberKnife and Radixact platforms, which are designed to deliver precise, image-guided treatments for tumors and other complex clinical cases.

Company

About Accuray, Inc.

Accuray Incorporated is a medical device company that develops, manufactures, sells, and supports advanced radiation therapy systems for cancer treatment. The company’s portfolio centers on the CyberKnife and Radixact platforms, which are designed to deliver precise, image-guided treatments for tumors and other complex clinical cases. Accuray also provides treatment planning software, motion management tools, and service offerings that support hospitals, cancer centers, and academic medical institutions. Its products are used across radiation oncology, stereotactic radiosurgery, and other specialized treatment workflows, giving the company a role in the broader market for precision oncology technologies. Accuray Incorporated focuses on combining hardware, software, and clinical support to help healthcare providers deliver targeted radiation therapy with greater accuracy and flexibility.

CEO Mr. Stephen R. LaNeve MBA · 809 employees · United States · https://www.accuray.com